Chinese consensus on gastroesophageal reflux disease

Chinese Journal of Gastroenterology

Volumn 12, Issue 4, 2007, Pages 233-239

  Lin, Sanren ^a   Xu, Guoming ^a   Hu, Pinjin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ARTICLE; BARRETT ESOPHAGUS; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; DYSPEPSIA; ENDOSCOPY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; LIFESTYLE; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK FACTOR; SOCIAL PSYCHOLOGY; STOMACH FUNDOPLICATION;

EID: 35248812897     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol, 2006, 101 (8): 1900-1920.
2. Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol, 2005, 19 (1): 15-35.
3. Guidelines for the diagnosis and management of Barrett' s columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology. http://www.bsg.org.uk (accessed 17 January 2006).
4. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol, 2005, 100 (1): 190-200.
5. Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol, 2004, 19 (4): 357-367.
6. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol, 2002, 97 (8): 1901-1909.
7. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology, 1996, 111 (1): 85-92.
8. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl, 1999, 231: 29-37.
9. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2005, 54 (5): 710-717.
10. Bretagne JF, Richard-Molard B, Honnorat C, et al. Gastroesophageal reflux in the French general population: national survey of 8000 adults. Presse Med, 2006, 35 (1 Pt 1): 23-31.
11. Ponce J, Vegazo O, Beltran B, et al. Prevalence of gastrooesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther, 2006, 23 (1): 175-184.
12. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med, 2001, 161 (1): 45-52.
13. Schwenkglenks M, Marbet UA, Szucs TD. Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based study. Soz Praventivmed, 2004, 49 (1): 51-61.
14. Fujiwara Y, Higuchi K, Watanabe Y, et al. Prevalence of gastroesophageal reflux disease and gastroesophageal reflux disease symptoms in Japan. J Gastroenterol Hepatol, 2005, 20 (1): 26-29.
15. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol, 2005, 100 (4): 747-753.
16. Lim SL, Goh WT, Lee JM, et al. Changing prevalence of gastroesophageal reflux with changing time: longitudinal study in an Asian population. J Gastroenterol Hepatol, 2005, 20 (7): 995-1001.
17. Chen M, Xiong L, Chen H, et al. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol, 2005, 40 (7): 759-767.
18. Chinese source.
19. Goh KL, Chang CS, Fock KM, et al. Gastro-oesophageal reflux disease in Asia. J Gastroenterol Hepatol, 2000, 15 (3): 230-238.
20. Kang JY, Tay HH, Yap I, et al. Low frequency of endoscopic esophagitis in Asian patients. J Clin Gastroenterol, 1993, 16 (1): 70-73.
21. Maekawa T, Kinoshita Y, Okada A, et al. Relationship between severity and symptoms of reflux oesophagitis in elderly patients in Japan. J Gastroenterol Hepatol, 1998, 13 (9): 927-930.
22. Yi SY, Lee SK, Kim MH, et al. Epidemiologic study of reflux esophagitis in general health screening people. Korean J Med, 1994, 46: 514-520.
23. Chinese source.
24. Chinese source.
25. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med, 1995, 27 (1): 67-70.
26. Kennedy T, Jones R. The prevalence of gastrooesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther, 2000, 14 (12): 1589-1594.
27. Haque M, Wyeth JW, Stace NH, et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J, 2000, 113 (1110): 178-181.
28. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther, 2005, 21 (7): 821-827.
29. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, et al. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther, 2004, 19 (1): 95-105.
30. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther, 2003, 18 (6): 595-604.
31. Locke GR 3rd, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med, 1999, 106 (6): 642-649.
32. Chinese source.
33. Chinese source.
34. Castell DO, Murray JA, Tutuian R, et al. Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther, 2004, 20 Suppl 9: 14-25.
35. Cremonini F, Talley NJ. Review article: the overlap between functional dyspepsia and irritable bowel syndrome - a tale of one or two disorders? Aliment Pharmacol Ther, 2004, 20 Suppl 7: 40-49.
36. Chinese source.
37. Chinese source.
38. Chinese source.
39. Chinese source.
40. Chinese source.
41. Chinese source.
42. Chinese source.
43. Chinese source.
44. Chinese source.
45. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut, 1994, 35 (1): 8-14.
46. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther, 2003, 17 (4): 537-545.
47. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology, 2006, 130 (5): 1459-1465.
48. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology, 2004, 127 (1): 310-330.
49. Egger K, Werner M, Meining A, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut, 2003, 52 (1): 18-23.
50. Paris Workshop on Columnar Metaplasia in the Esophagus and the Esophagogastric Junction, Paris, France, December 11-12 2004. Endoscopy, 2005, 37 (9): 879-920.
51. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med, 1976, 295 (9): 476-480.
52. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol, 2000, 24 (2): 167-176.
53. Sharma P, Morales TG, Sampliner RE. Short segment Barrett' s esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol, 1998, 93 (7): 1033-1036.
54. Richter JE. Short segment Barrett's esophagus: ignorance may be bliss. Am J Gastroenterol, 2006, 101 (6): 1183-1185.
55. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol, 2004, 39 (12): 1175-1179.
56. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol, 1989, 24 (4): 401-406.
57. Paul K, Redman CM, Chen M. Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. Aliment Pharmacol Ther, 2001, 15 (10): 1571-1577.
58. Ciociola AA, Pappa KA, Sirgo MA. Nonprescription doses of ranitidine are effective in the relief of episodic heartburn. Am J Ther, 2001, 8 (6): 399-408.
59. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev, 2004, 18 (4): CD002095.
60. Bour B, Staub JL, Chousterman M, et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther, 2005, 21 (7): 805-812.
61. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med, 2003, 114 (1): 1-5.
62. Galmiche JP, Bruley des Varannes S. Endoluminal therapies for gastro-oesophageal reflux disease. Lancet, 2003, 361 (9363): 1119-1121.